Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study

ESC Heart Failure
Thor UelandNils Bolstad

Abstract

Neuroendocrine activation is associated with poor outcome in heart failure (HF). The neuropeptide gastrin-releasing peptide (GRP), derived from the precursor proGRP1-125 (proGRP), has recently been implicated in inflammation and wound repair. We investigated the predictive value of proGRP on clinical outcomes in HF patients with reduced ejection fraction. The association between plasma proGRP (time-resolved immunofluorometric assay) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anaemia, enrolled in the Reduction of Events by Darbepoetin alfa in Heart Failure (RED-HF) trial. Median proGRP levels in the RED-HF cohort were markedly increased [95 ng/L (25th, 75th percentile, 69-129 ng/L)] with 64% patients above the 80 ng/L reference limit. Baseline proGRP correlated with estimated glomerular filtration rate (r = 0.52), N terminal pro brain natriuretic peptide (r = 0.33), troponin T (r = 0.34), and haemoglobin (r = 0.16) (all P < 0.001). The incidence outcome increased with increasing tertiles of baseline proGRP (primary endpoint third tertile vs. the lowest tertile;...Continue Reading

References

Jul 31, 1998·The New England Journal of Medicine·E R LevinW K Samson
Oct 10, 1998·Respirology : Official Journal of the Asian Pacific Society of Respirology·H NakahamaM Sugita
Dec 5, 2003·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·H Mehmet TurkN Mehmet Buyukberber
May 14, 2004·American Journal of Physiology. Renal Physiology·Chelsea DumesnyArthur Shulkes
May 21, 2005·The International Journal of Developmental Biology·Hiroko Ohki-HamazakiFumihiko Maekawa
Sep 30, 2005·American Journal of Respiratory and Critical Care Medicine·Felipe Dal-PizzolGilberto Schwartsmann
Nov 29, 2005·European Journal of Heart Failure·Feridun KosarErcan Varol
Apr 11, 2006·American Journal of Respiratory and Critical Care Medicine·Khalid AshourMary E Sunday
Apr 30, 2008·Clinical Chemistry·Marianne S NordlundElisabeth Paus
May 6, 2008·Peptides·A BaroniM Cartenì
May 19, 2009·International Journal of Cardiology·Okan TurgutAhmet Gurlek
Jul 28, 2009·European Journal of Heart Failure·John J V McMurrayUNKNOWN RED-HF Committees and Investigators
Sep 15, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yen-Hung LinMing-Fong Chen
Jun 7, 2011·International Journal of Cardiology·Thor UelandLars Gullestad
Nov 24, 2011·Heart Failure Clinics·Irving H ZuckerHarold D Schultz
Dec 6, 2011·Journal of cardiology·Yukihito SatoYoshiki Takatsu
Dec 6, 2011·Circulation·Serge MassonUNKNOWN Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca–H
Jan 19, 2013·European Journal of Heart Failure·John J V McMurrayUNKNOWN RED-HF Committees Investigators
Mar 12, 2013·The New England Journal of Medicine·Karl SwedbergUNKNOWN RED-HF Investigators
Jan 1, 2014·Cancer Metastasis Reviews·J CapdevilaA Scarpa
Mar 14, 2014·JACC. Heart Failure·Rudolf A de BoerHerman H W Silljé
Nov 22, 2016·ESC Heart Failure·Vijaiganesh NagarajanSula Mazimba

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00358215

Software Mentioned

RED
SAS

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.